GABA (γ-amino butyric acid) is the predominant inhibitory neurotransmitter in the central nervous system. Metabotropic GABA~B~ receptor is a G-protein coupled receptor (GPCR) that mediates slow and prolonged synaptic inhibition through G~i/o~ protein^[@R1],[@R2]^. Presynaptic GABA~B~ receptor suppresses neurotransmitter release, and postsynaptic GABA~B~ receptor causes hyperpolarization of neurons^[@R1],[@R2]^. Malfunction of GABA~B~ receptor can lead to various neurological disorders, including spasticity, epilepsy, and pain^[@R1]--[@R3]^. Baclofen, a selective GABA~B~ agonist, is used clinically to treat muscle spasticity associated with multiple sclerosis, cerebral palsy, and spinal cord injury^[@R1]--[@R3]^.

GABA~B~ receptor belongs to the distinct class C GPCR family^[@R4]^. Ligand-binding to these receptors takes place within a large extracellular Venus Flytrap (VFT) module that has sequence homology to bacterial periplasmic amino acid binding proteins (PBPs)^[@R4]^. Unlike metabotropic glutamate receptors (mGluRs) and extracellular calcium sensing receptor, which function as disulfide-tethered homodimers^[@R5]--[@R8]^, GABA~B~ and taste receptors act as heterodimers^[@R9]--[@R16]^.

GABA~B~ receptor functions as a heterodimeric assembly of GBR1 and GBR2 subunits^[@R9]--[@R12],[@R14]^. GBR2 facilitates cell surface expression of GBR1 by masking an endoplasmic reticulum retention signal of GBR1^[@R17],[@R18]^. GBR1 is responsible for ligand recognition through its extracellular domain^[@R19],[@R20]^. Although GBR2 does not bind any known GABA~B~ ligand^[@R9]--[@R11],[@R21]^, its ectodomain directly interacts with the GBR1 ectodomain to enhance agonist affinity^[@R10],[@R11],[@R22]--[@R26]^ and is required for receptor activation^[@R22],[@R25],[@R27]^. Finally, the transmembrane domain of GBR2 is responsible for G-protein coupling^[@R22],[@R25],[@R28]--[@R32]^.

Most of the current knowledge about class C GPCR structures derives from homodimeric mGluRs. The ectodomain structures of three mGluR subtypes have been determined with and without ligand^[@R33]--[@R35]^. Here we assembled a stable heterodimeric complex of the human GBR1 and GBR2 ectodomains, and determined its crystal structure in the absence of ligand and in the presence of various agonists and antagonists. Together with our mutational data, these structures provide insights into the molecular mechanisms of receptor heterodimerization, ligand recognition, and receptor activation.

Structures of GABA~B~ heterodimer {#S1}
=================================

The extracellular VFT module of human GBR1b (GBR1b~VFT~) and GBR2 (GBR2~VFT~) were co-secreted as a heterodimeric complex from insect cells ([Supplementary Fig. 1](#SD2){ref-type="supplementary-material"}). The GBR1b~VFT~:GBR2~VFT~ heterodimer binds various agonists and antagonists with the same rank order of affinities as the full-length receptor, indicating that it is physiologically relevant^[@R26]^.

We determined the crystal structure of the GBR1b~VFT~:GBR2~VFT~ complex in the apo form, bound to six different antagonists (CGP54626~ANT~, CGP46381~ANT~, CGP35348~ANT~, SCH50911~ANT~, (S)-2-OH-saclofen~ANT~, and (R)-phaclofen~ANT~), and bound to two different agonists (endogenous ligand GABA and clinical drug (R)-baclofen~AGO~) ([Supplementary Table 1](#SD2){ref-type="supplementary-material"}). Each structure consists of a non-covalent heterodimer of GBR1b~VFT~ and GBR2~VFT~, wherein the two subunits "dance cheek-to-cheek": the protomers are bound to each other such that they are side by side and facing opposite directions ([Fig. 1a--c](#F1){ref-type="fig"}; [Supplementary Fig. 2](#SD2){ref-type="supplementary-material"}). All of the agonists and antagonists bind in the crevice between the LB1 and LB2 domains of GBR1b~VFT~.

GBR1b~VFT~ and GBR2~VFT~ have similar overall structures, in agreement with their sequence homology (33% identity) ([Supplementary Fig. 3](#SD2){ref-type="supplementary-material"}). Both subunits have a bi-lobed architecture related to that found in mGluRs^[@R33]--[@R35]^, natriuretic peptide receptors^[@R36],[@R37]^, ionotropic glutamate receptors^[@R38]--[@R40]^ and PBPs^[@R41]^. However, the extracellular domains of GBR1b and GBR2 lack the cysteine-rich region found at the C-terminal end of mGluR ectodomains. Each GABA~B~ subunit contains two distinct domains, LB1 and LB2. The individual LB1 and LB2 domains of the two subunits exhibit high correlation with each other.

Despite similarities, the GBR1b~VFT~ and GBR2~VFT~ structures have different interdomain arrangements, consistent with their disparate ligand-binding characteristics ([Fig. 2a, b](#F2){ref-type="fig"}). The ligand-binding subunit GBR1b~VFT~ can oscillate between open and closed conformations, wherein the more compact closed conformation is associated with agonist binding. In contrast, the non-ligand binding subunit GBR2~VFT~ has nearly identical conformations with and without dimer partner GBR1~VFT~.

In the crystal structure of apo-GBR1b~VFT~:GBR2~VFT~, both subunits adopt an open conformation when compared with the known structures of mGluRs^[@R33]--[@R35]^ ([Supplementary Fig. 4](#SD2){ref-type="supplementary-material"}). All six antagonist-bound structures closely resemble that of the apo complex, both in the arrangement of the heterodimer and in the structures of the individual subunits ([Supplementary Fig. 4](#SD2){ref-type="supplementary-material"}). The ligand-binding cleft of GBR1b~VFT~ stays open with each bound antagonist. In addition, GBR2~VFT~ remains wide open with an empty interdomain cleft. This open-open configuration of the apo and antagonist-bound structures corresponds to the resting (or inactive) state of the heterodimeric receptor.

Agonist binding causes large conformational changes within the heterodimeric complex. First, both the agonists GABA and (R)-baclofen~AGO~ induce domain closure of GBR1b~VFT~, as previously predicted^[@R42]^ ([Fig. 2a](#F2){ref-type="fig"}). When the LB1 domains of apo and agonist-bound GBR1b~VFT~ are superimposed, their LB2 domains can be related by a 29°-rotation about a nearly horizontal interdomain axis. Since the rotational axis has a slight vertical offset, this transformation also brings the LB2 domain of GBR1b~VFT~ into close contact with the LB2 domain of GBR2~VFT~ to form a large heterodimer interface unique to the active state.

Second, GBR2~VFT~ remains open in the agonist-bound state, consistent with our previous prediction that GBR2~VFT~ has a constitutively open conformation^[@R26]^. Nevertheless, the LB2 domain of GBR2~VFT~ undergoes a twist motion of 9° around a nearly vertical axis, and moves toward the LB2 domain of GBR1b~VFT~ to form new heterodimeric contacts ([Fig. 2b](#F2){ref-type="fig"}).

Finally, the substantial rearrangement of the LB2 domains from the apo to the agonist-bound state shortens the distance between the C-termini of the two subunits from 45 Å to 32 Å ([Fig. 2c, d](#F2){ref-type="fig"}; [Supplementary Fig. 5](#SD2){ref-type="supplementary-material"}). This decrease in the separation between membrane proximal LB2 domains may lead to changes in the relative orientation of the transmembrane domains. In summary, both agonist-bound GBR1b~VFT~:GBR2~VFT~ complexes adopt a closed-open structural arrangement, which corresponds to the active state of the receptor ([Supplementary Fig. 4](#SD2){ref-type="supplementary-material"}).

Common subunit-subunit interactions {#S2}
===================================

In both the resting and active states, GBR1b~VFT~ and GBR2~VFT~ interact through their LB1 domains ([Supplementary Fig. 6, 7](#SD2){ref-type="supplementary-material"}). In the apo and antagonist-bound structures, the subunit association is exclusively facilitated by this LB1-LB1 contact. The heterodimer buries over 1,400 Å^2^ of solvent accessible surface area and exhibits exceptionally high interfacial shape correlation ([Supplementary Table 2](#SD2){ref-type="supplementary-material"}).

The LB1-LB1 interaction is mediated by the B and C helices of both subunits ([Fig. 3a](#F3){ref-type="fig"}). The heterodimer interface can be divided into three regions ([Fig. 3b](#F3){ref-type="fig"}). Site I is located at the center of the interface, and it is flanked by sites II and III on each side.

Site I is comprised of a central hydrophobic patch surrounded by hydrogen bonds. The heterodimer contacts within this site are highly conserved in all of the GBR1b~VFT~:GBR2~VFT~ structures. In particular, it features three deeply buried tyrosine residues (Y113 and Y117 of GBR1b~VFT~, and Y118 of GBR2~VFT~) that are critical for heterodimer interaction and receptor activation^[@R26]^. These tyrosine residues participate in aromatic stacking interactions, and form interfacial hydrogen bonds. Together with the adjacent lysine and tryptophan residues, they are responsible for the majority of hydrophobic contacts at the LB1-LB1 heterodimer interface.

Site II interactions are mostly hydrogen bonds, and include a universal salt bridge (GBR1b~VFT~-R141 : GBR2~VFT~-D109) as well as a conserved hydrogen bond (GBR1b~VFT~-E138 : GBR2~VFT~-N110). Site III consists predominantly of water-mediated contacts, and is the most variable part of the LB1-LB1 interface.

Agonist-induced heterodimer interface {#S3}
=====================================

Agonist binding induces the formation of an additional heterodimer interface between the LB2 domains of GBR1b~VFT~ and GBR2~VFT~ subunits ([Supplementary Fig. 7](#SD2){ref-type="supplementary-material"}). This is consistent with our calorimetry measurements showing that GBR2~VFT~ has higher affinity for agonist-bound than antagonist-bound GBR1b~VFT~^[@R26]^. The LB2-LB2 interface buries over 1,300 Å^2^ of solvent accessible surface area, has poor shape complementarity, and is dominated by polar interactions ([Supplementary Table 2](#SD2){ref-type="supplementary-material"}).

The LB2-LB2 interaction is mediated by two strand-loop-helix motifs from each LB2 domain ([Fig. 3c](#F3){ref-type="fig"}). The neighboring strands f and g are part of the central β-sheet in LB2, and helices F and G flank the β-sheet. The heterodimer contacts consist primarily of hydrogen bonds, some of which are mediated by water molecules. The interface can be divided into three adjacent areas ([Fig. 3d](#F3){ref-type="fig"}). Sites IV and V each feature a large cluster of hydrogen bonds, while site VI mostly consists of isolated contacts. The GBR2~VFT~ residue N213 is located at the intersection of sites IV and V, and it bridges the hydrogen bond networks within these two regions. In addition, a minor LB2-LB1 contact involving helix D of GBR2~VFT~ is formed at the edge of site IV.

To confirm the importance of the LB2-LB2 heterodimer interface to receptor activation, we carried out alanine scanning mutagenesis of the interfacial residues. We identified several polar residues from each subunit that are critical to agonist-dependent G~i~ protein activity ([Supplementary Fig. 7](#SD2){ref-type="supplementary-material"}). These include the GBR1b~VFT~ residues T198, E201 and S225, and the GBR2~VFT~ residues D204, Q206, N213 and S233. All of these residues are engaged in multiple interfacial hydrogen bonds at the LB2-LB2 interface. This reliance on hydrophilic interactions to form a distinct subunit interface in the active state allows the receptor to readily dissociate upon returning to its resting state. Previous studies have also shown that introduction of a large N-glycan into the LB2 domain of either GABA~B~ subunit inhibits agonist-induced receptor activation^[@R43]^.

Ligand recognition {#S4}
==================

All of the antagonists are derivatives of GABA, and have the general structure of a γ-amino acid. The receptor-antagonist interactions are mediated largely by hydrogen bonds ([Fig. 4a, b](#F4){ref-type="fig"}; [Supplementary Fig. 8](#SD2){ref-type="supplementary-material"}). First, each antagonist is anchored at the crevice of GBR1b~VFT~ by two sets of hydrogen bonds. The α-acid group at one end forms hydrogen bonds with the LB1 residues S130 and S153; the γ-amino group at the other end is hydrogen-bonded to H170 and E349. Second, W65 makes van der Waals contacts with all of the antagonists. Third, the β-hydroxyl substituent of CGP54626~ANT~ and (S)-2-OH-saclofen makes additional hydrogen bonds with the receptor that are specific to these antagonists. Finally, all of the antagonists except SCH50911~ANT~ and (R)-phaclofen~ANT~ participate in water-mediated interaction with S131. These extensive contacts indicate that the LB1 domain is primarily responsible for anchoring antagonist.

In contrast, the interaction between the LB2 domain and bound antagonist is sparse and varies among the different antagonists ([Supplementary Fig. 8](#SD2){ref-type="supplementary-material"}). Only two antagonists, CGP54626~ANT~ and SCH50911~ANT~, directly contact W278 of LB2 through a large γ-substituent. As a result of this additional LB2 interaction, both compounds have higher binding affinity to GABA~B~ receptor than the other antagonists reported here^[@R3]^. This suggests that the LB2 domain plays an auxiliary role in antagonist recognition, and enhances the potency of selective antagonists.

GABA~B~ receptor recognizes both the agonists GABA and (R)-baclofen~AGO~ in essentially the same manner ([Fig. 4c, d](#F4){ref-type="fig"}; [Supplementary Fig. 9](#SD2){ref-type="supplementary-material"}). (R)-baclofen~AGO~ is a derivative of GABA, and contains a chlorophenyl substituent at the β-position. Like the antagonists, each agonist is secured by two hydrogen bond networks, one at each end of the molecule. Furthermore, a common set of LB1 residues are involved in binding the two ends of all of the agonists and antagonists. Unlike the antagonists, both agonists also directly contact two key residues of the LB2 domain, Y250 and W278. In addition, the two tryptophan residues W65 and W278 make extensive van der Waals contacts with both GABA and (R)-baclofen~AGO~. Therefore, both the LB1 and LB2 domains are required for agonist recognition.

The binding sites of GABA and (R)-baclofen~AGO~ differ in the side chain conformation of the LB2 residue W278 ([Supplementary Fig. 9](#SD2){ref-type="supplementary-material"}). Relative to its orientation in the GABA-bound complex, the indole ring of W278 is flipped \~170° to accommodate the β-chlorophenyl substituent of (R)-baclofen~AGO~, which forms aromatic ring-stacking interactions with both Y250 and W278. In contrast, GABA makes van der Waals contact with W278 alone through its aliphatic backbone. The conformational adaptability of W278 provides a mechanism by which the receptor recognizes structurally different ligands while maintaining ligand-binding specificity and affinity.

Agonist versus antagonist action {#S5}
================================

The function of a GABA~B~ agonist is to stabilize the closed conformation of GBR1b~VFT~, while that of an antagonist is to confine the GBR1b~VFT~ subunit to the open configuration ([Supplementary Fig. 10](#SD2){ref-type="supplementary-material"}). Agonist-bound GBR1b~VFT~ has a closed cleft; the agonist is buried and inaccessible to the bulk solvent. In contrast, antagonist-bound GBR1b~VFT~ has an open cleft, and the antagonist is solvent accessible.

The presence of a bulky substituent in each antagonist inhibits domain closure of GBR1b~VFT~. The highly potent antagonist CGP54626~ANT~ contains an α-cyclohexyl and a γ-dichlorophenyl group. The adverse interactions of these moieties with Y250 and W278 would be expected to prevent the LB1 and LB2 domains from approaching each other ([Fig. 4e](#F4){ref-type="fig"}). Similarly, each of the other antagonists CGP46381~ANT~, CGP35348~ANT~, and SCH50911~ANT~ has a bulky substituent at either the α- or γ-position to block GBR1b~VFT~ domain closure ([Supplementary Fig. 8, 9](#SD2){ref-type="supplementary-material"}). Although the antagonists (S)-2-OH-saclofen~ANT~ and (R)-phaclofen~ANT~ are structurally analogous to the agonist (R)-baclofen~AGO~, their α-acid motifs assume a tetrahedral coordination geometry that is incompatible with the active-state conformation of Y250 ([Fig. 4f](#F4){ref-type="fig"}). Furthermore, the α-substituents push the β-chlorophenyl ring toward the γ-amino end of each antagonist, thereby generating potential steric interactions with I276 and W278 to prevent GBR1b~VFT~ domain closure.

All of the residues at the ligand-binding site are conserved within GBR1 sequences across different species ([Supplementary Fig. 11](#SD2){ref-type="supplementary-material"}). Some of the ligand-binding residues have been implicated by previous studies, including S130, G151, S153 and E349 of GBR1b^[@R21],[@R26],[@R44]--[@R46]^.

The LB1 residues are required for both agonist and antagonist recognition. We found that the W65A substitution caused substantial loss of ligand binding and receptor function, ([Fig. 4g, h](#F4){ref-type="fig"}). The H170A mutation essentially abolished antagonist binding, and lowered the maximum agonist-induced \[^35^S\]GTPγS binding to half that of wild-type level ([Fig. 4g, h](#F4){ref-type="fig"}). These data indicate that both W65 and H170 are indispensable for ligand recognition.

The LB2 residues are essential for agonist binding. First, the W278A mutant retained the ability to bind the antagonist \[^3^H\]CGP54626~ANT~, although with decreased potency ([Fig. 4g](#F4){ref-type="fig"}). This is consistent with the auxiliary role of W278 in antagonist recognition. On the other hand, this mutation is detrimental to receptor activation, since it not only reduced the maximum GABA-dependent \[^35^S\]GTPγS binding, but also increased the half effective concentration (EC~50~) of GABA by more than 500-fold ([Fig. 4h](#F4){ref-type="fig"}). Second, the Y250A mutation had no effect on antagonist binding, in agreement with our structural observations ([Fig. 4g](#F4){ref-type="fig"}). However, it decreased the agonist response, and increased the EC~50~ of GABA by more than 100-fold ([Fig. 4h](#F4){ref-type="fig"}). These data indicate that both Y250 and W278 are critical to agonist recognition.

Implications for receptor activation {#S6}
====================================

Structural comparison indicates that the concept of major inter-subunit relocation that holds for the activation of mGluRs cannot be applied to GABA~B~ receptor. The extracellular domains of these receptors share a common mode of dimerization through their LB1 domains ([Supplementary Fig. 12, 13](#SD2){ref-type="supplementary-material"}). The resting and active configurations of mGluRs differ by a 70°-rotation in dimer orientation^[@R33]--[@R35]^. Both closed-open and closed-closed conformations have been reported for activated mGluRs^[@R33]--[@R35]^, although full activation requires the closure of both protomers^[@R47]^. In contrast, the heterodimeric LB1-LB1 interface of GABA~B~ receptor undergoes a minor 5°-rearrangement upon agonist binding, and the receptor only adopts a closed-open active conformation. Our data indicate that activation of GABA~B~ receptor involves the formation of a novel LB2-LB2 heterodimer interface.

We carried out disulfide crosslinking studies^[@R48]^ to determine the physiological relevance of the LB2-LB2 interaction in full length receptor. Based on the active-state structure of GBR1b~VFT~:GBR2~VFT~, we introduced cysteine mutations into a residue pair across the LB2-LB2 dimer interface (GBR1-T198C and GBR2-Q206C), which had the proximity and geometry required for disulfide formation ([Fig. 5a](#F5){ref-type="fig"}). Western blot analysis indicates that co-expression of wild-type GBR1b and GBR2 or the combination of a single cysteine mutant with its wild-type partner in mammalian cells produced monomeric protein bands in the presence of GABA under both reducing and non-reducing conditions (\~95 kDa for GBR1b; \~115 kDa for GBR2) ([Fig. 5b](#F5){ref-type="fig"}). In contrast, co-expression of the cysteine mutant pair yielded a heterodimeric protein band (\~210 kDa) under non-reducing conditions ([Fig. 5b](#F5){ref-type="fig"}). This band was recognized by both anti-Flag and anti-HA antibodies, which were used to detect differentially tagged GBR1b and GBR2 subunits. Furthermore, it was observed in the absence of ligand and in the presence of the agonist GABA. These observations indicate the spontaneous formation of a disulfide-tethered GBR1b-GBR2 heterodimer, and confirm that the LB2-LB2 interface observed in the active-state GBR1b~VFT~:GBR2~VFT~ structure is also present in free and agonist-bound native GABA~B~ receptor.

To determine the functional effects of locking the LB2-LB2 interface, we measured agonist-dependent G~i~ protein activation of different combinations of wild-type and cysteine mutant receptors ([Fig. 5c](#F5){ref-type="fig"}). For the wild-type receptor and single cysteine mutants, application of GABA led to stimulation of \[^35^S\]GTPγS binding both in the absence and presence of dithiothreitol (DTT). In contrast, the double cysteine mutant exhibited constitutive activity under non-reducing conditions, and addition of GABA did not further increase its functional activity ([Fig. 5c](#F5){ref-type="fig"}). This indicates that the inter-subunit disulfide bond holds the receptor in a fully active form. Indeed, upon reduction of the disulfide bond, the double cysteine mutant receptor lost its constitutive activity, but regained sensitivity to GABA to a level comparable to that of a single cysteine mutant ([Fig. 5c](#F5){ref-type="fig"}). Our data demonstrate that formation of the LB2-LB2 interface is both necessary and sufficient for GABA~B~ receptor activation.

In the conformational equilibrium of GABA~B~ receptor, an antagonist maintains the inactive conformation of the receptor, while an agonist stabilizes its active conformation ([Supplementary Fig. 14](#SD2){ref-type="supplementary-material"}). Agonist binding to GABA~B~ receptor induces domain closure in the GBR1 subunit, an expansion of the heterodimer interaction to include a large LB2-LB2 interface, and a decrease in the separation between the membrane-proximal LB2 domains. Since receptor function is not affected by alterations in the peptide linker between the VFT and transmembrane domains of each subunit^[@R27]^, these changes would likely be directly relayed to the transmembrane domains. We expect that the transmembrane domains of the GABA~B~ subunits exist as pre-formed heterodimers on the cell surface because both the extracellular and intracellular components form stable heterodimers^[@R12],[@R23],[@R24],[@R26],[@R49]^. Therefore, agonist-induced conformational changes may lead to a rearrangement of the transmembrane domain heterodimer for signal transduction across the membrane. This novel activation mechanism would be, as of yet, unique to inhibitory GABA~B~ receptor.

Methods {#S8}
=======

Protein expression and purification {#S9}
-----------------------------------

The extracellular domains of human GBR1 and GBR2 were separately cloned into the pFBDM vector^[@R50]^ for expression in baculovirus-infected insect cells. The GBR1 isoform GBR1b^[@R19]^ was used in this study. The GBR1b~VFT~ construct contained residues 48--459, with the signal peptide of baculovirus envelope surface glycoprotein gp67 attached at the N-terminus and a Flag tag at the C-terminus. The GBR2~VFT~ construct contained residues 1--466 and a C-terminal Flag tag, as previously described^[@R26]^.

Sf9 insect cells were co-infected with recombinant GBR1b~VFT~ and GBR2~VFT~ baculoviruses at 23°C for 96 hours. The GBR1b~VFT~:GBR2~VFT~ complex was purified from cell supernatant by anti-Flag antibody (M2) affinity chromatography followed by gel filtration chromatography (Superdex 200, GE Healthcare). The CGP54626~ANT~-GBR1b~VFT~:GBR2~VFT~ complex was produced in the presence of 10 µM CGP54626~ANT~ throughout expression and 20 µM CGP54626~ANT~ during purification. The (R)-baclofen~AGO~-GBR1b~VFT~:GBR2~VFT~ complex was expressed and purified in the presence of 100 µM (R)-baclofen, and the GABA-GBR1b~VFT~:GBR2~VFT~ complex was produced in the presence of 100 µM GABA.

Crystallization and data collection {#S10}
-----------------------------------

Crystals of the apo-GBR1b~VFT~:GBR2~VFT~ complex were grown at 4°C in 10% PEG 3350, 20% glycerol and 0.12 M Na acetate, pH 7.0. Crystals of various antagonist-bound GBR1b~VFT~:GBR2~VFT~ complexes were obtained under the same condition as the apo complex. Specifically, the CGP54626~ANT~-bound heterodimer was crystallized using protein that was purified in the presence of CGP54626~ANT~. The apo-GBR1b~VFT~:GBR2~VFT~ complex was also co-crystallized with 10 mM of each of the following antagonists: CGP46381~ANT~, CGP35348~ANT~, SCH50911~ANT~, (R, S)-2-OH-saclofen~ANT~, and (R, S)-phaclofen~ANT~. All of the crystals were directly frozen from drops.

The agonist-bound (R)-baclofen~AGO~-GBR1b~VFT~:GBR2~VFT~ complex was crystallized at 20°C from 20% PEG 2000, 15% glycerol, 0.2 M NH~4~Cl, and 0.1 M Na cacodylate, pH 5.2, in the presence of 10 mM (R)-baclofen. Crystals of the GABA-GBR1b~VFT~:GBR2~VFT~ complex were grown at 20°C from 18% PEG 2000, 5% glycerol, 0.15 M NH~4~Cl, and 0.1 M Na cacodylate, pH 5.0, in the presence of 10 mM GABA. The crystals were frozen in a cryoprotecting solution containing 20% glycerol and all other components of the crystallization solution.

Native data for the different complexes were collected at the 24ID-C and 24ID-E beamlines of Advanced Photon Source (APS). Diffraction data for the apo, CGP46381~ANT~-, CGP35348~ANT~-, SCH50911~ANT~-, and GABA-bound complexes were integrated using XDS^[@R51]^ and scaled with SCALA^[@R52]^. Data for the CGP54626~ANT~-, (S)-2-OH-saclofen~ANT~-, (R)-phaclofen~ANT~-, and (R)-baclofen~AGO~-bound complexes were integrated and scaled using HKL2000^[@R53]^.

Structure determination {#S11}
-----------------------

The structure of the apo-GBR1b~VFT~:GBR2~VFT~ complex was solved by molecular replacement. The position of GBR2~VFT~ was identified using the free GBR2~VFT~ structure (PDB code 4F11)^[@R26]^ as the search model. The location of GBR1b~VFT~ was found using the individual LB1 and LB2 domains of GBR2~VFT~ as the search probes. A complete atomic model of the apo-GBR1b~VFT~:GBR2~VFT~ complex was developed through a succession of manual building and iterative refinement. The final model contained the GBR1b~VFT~ residues 48--368 and 377--459, the GBR2~VFT~ residues 53--292, 300--379 and 385--466, and part of the Flag tag at the C-termini of both subunits. Carbohydrate residues were also attached to Asn323 and Asn365 of GBR1b~VFT~, and Asn404 of GBR2~VFT~.

All of the antagonist-bound GBR1b~VFT~:GBR2~VFT~ structures were solved by molecular replacement using the apo-GBR1b~VFT~:GBR2~VFT~ structure as the search model. For each complex, the bound antagonist was modeled into the residual electron density map obtained in the final rounds of refinement. All of the antagonist-bound structures contained the GBR1b~VFT~ residues 48--368 and 377--459, the GBR2~VFT~ residues 53--292, 300--379 and 385--466, and part of the Flag tag at the C-termini of both subunits. Carbohydrate residues were also attached to Asn323 and Asn365 of GBR1b~VFT~, and Asn404 of GBR2~VFT~. Although a racemic mixture (R, S)-2-OH-saclofen~ANT~ was used for crystallization, only the (S)-2-OH-saclofen~ANT~ enantiomer was bound to GBR1b~VFT~ in the structure. Our observation is consistent with previous findings that (S)-2-OH-saclofen~ANT~ enantiomer is the active antagonist^[@R54]^. Similarly, we found that (R)-phaclofen was the active enantiomer, in agreement with previous studies^[@R55]^.

The structure of the (R)-baclofen~AGO~-GBR1b~VFT~:GBR2~VFT~ complex was also determined by molecular replacement. The position of GBR2~VFT~ was found using the GBR2~VFT~ structure from the apo complex as the search model. The (R)-baclofen~AGO~-bound GBR1b~VFT~ molecule was located using the individual LB1 and LB2 domains of apo-GBR1b~VFT~ as the search probes. A complete model of the (R)-baclofen~AGO~-GBR1b~VFT~:GBR2~VFT~ complex was constructed through iterative rounds of manual building and refinement. The GABA-bound GBR1b~VFT~:GBR2~VFT~ structure was solved using the refined (R)-baclofen~AGO~-GBR1b~VFT~:GBR2~VFT~ complex structure as the search model. For each complex, the bound agonist was modeled into the residual electron density map obtained in the final rounds of refinement. The (R)-baclofen~AGO~-GBR1b~VFT~:GBR2~VFT~ complex contained the GBR1b~VFT~ residues 50--368 and 377--459; the GABA-GBR1b~VFT~:GBR2~VFT~ complex contained the GBR1b~VFT~ residues 50--84, 92--337, 344--368 and 377--459. Both agonist-bound structures contained the GBR2~VFT~ residues 50--291 and 302--466, and part of the Flag tag at the C-termini of both GBR1b~VFT~ and GBR2~VFT~. Carbohydrate residues were attached to Asn404 of GBR2~VFT~.

Molecular replacement searches were carried out using PHASER^[@R56]^. Model building was performed with COOT^[@R57]^. Structural refinement was executed using BUSTER^[@R58]^. Ramachandran statistics were calculated for each structure using MolProbity^[@R59]^. Pairwise structural comparison was performed using LSQMAN^[@R60]^. Software installation support was provided by SBGrid^[@R61]^.

Cell surface expression {#S12}
-----------------------

Full-length human GBR1b and GBR2 were individually cloned into a pcDNA3.1(+) vector (Invitrogen) for expression in human embryonic kidney (HEK293) cells. A Flag tag was inserted after the signal peptide of GBR1b, and an HA tag was placed after the signal peptide of GBR2. Mutants of GBR1b and GBR2 were constructed using the QuikChange mutagenesis system (Stratagene).

HEK293 T/17 cells (ATCC) were co-transfected by Lipofectamine 2000 (Invitrogen) with the GBR1b and GBR2 plasmids. Cells permeabilized with 0.5% Triton X100 were used to determine the total expression levels of GBR1b and GBR2 in transfected cells. Untreated cells were used to determine the cell surface expression level of each subunit. The amount of surface protein detected for each construct was normalized to that found in the total cell lysate.

The cells were blocked with 5% milk, and then incubated with mouse anti-Flag M1 antibody (Sigma) as the primary antibody to measure GBR1b expression. Similarly, mouse anti-HA antibody HA.11 clone 16B12 (Covance) was used to detect GBR2. Donkey anti-mouse IRDye 800-labeled antibody (LiCor) was used as the secondary antibody in both cases. Fluorescent signals were measured with an Odyssey Infrared Imager (LiCor). The results of three independent experiments were used for statistical analysis. All of the mutants reported here were expressed on the cell surface at levels comparable to that of wild-type GABA~B~ receptor.

Agonist-stimulated \[^35^S\]GTPγS binding {#S13}
-----------------------------------------

HEK293 T/17 cells were transiently transfected with full length GBR1b and GBR2 plasmids. The cells were harvested in 50 mM Hepes, pH 7.4 to obtain the membrane fraction. Membranes were suspended in an assay buffer containing 50 mM Tris pH 7.7, 100 mM NaCl, 12 mM MgCl~2~, 1.8 mM CaCl~2~, and 0.2 mM EGTA to approximately 400 µg protein per ml. The membrane homogenates were incubated with increasing concentrations of GABA in the presence of 10 µM GDP. \[^35^S\]GTPγS (1,250 Ci/mmol) was then added to a final concentration of 0.5 nM. After incubation at room temperature for 45 minutes, unbound \[^35^S\]GTPγS was removed by centrifugation. The amount of bound \[^35^S\]GTPγS was measured using a Beckman LS6500 liquid scintillation counter. Nonspecific binding was measured in the presence of 20 µM unlabeled GTPγS. Basal activity was determined in the absence of GABA. The basal activity of the wild-type receptor was used to calculate the percent stimulation of the double cysteine mutant receptor GBR1b-T198C/GBR2-Q206C under non-reducing conditions. The reduced \[^35^S\]GTPγS binding activity of the double cysteine mutant (\~60% of the wild-type value) could be attributed to the effect of the mutations themselves, since introduction of a single cysteine mutation into either subunit also caused a decrease in agonist response.

To measure \[^35^S\]GTPγS binding under reducing conditions, the membrane homogenates were pre-incubated with 1mM dithiothreitol (DTT) before the addition of various concentrations of GABA and 10 µM GDP. The presence of DTT reduced the basal activity of all different combinations of wild-type and cysteine mutant receptors. The percent stimulation of each receptor mutant was calculated based on the wild-type response obtained under the same condition. Data analysis was performed using the non-linear regression algorithms in Prism (GraphPad Software). Data points represent average ± s.e.m. of triplicate measurements.

Radioligand binding assay {#S14}
-------------------------

HEK293 T/17 cells were transiently transfected with full length GBR1b and GBR2 plasmids. Cell membranes were suspended in an assay buffer containing 20 mM Tris pH 7.4, 118 mM NaCl, 5.6 mM glucose, 1.2 mM KH~2~PO~4~, 1.2 mM MgSO~4~, 4.7 mM KCl, and 1.8 mM CaCl~2~ to approximately 400 µg protein per ml. \[^3^H\]CGP54626~ANT~ (25 Ci/mmol) was added to the reaction mixture to final concentrations ranging from 0.5 nM to 20 nM. After incubation at room temperature for 30 minutes, unbound \[^3^H\]CGP54626~ANT~ was removed by centrifugation. The amount of bound \[^3^H\]CGP54626~ANT~ was measured by liquid scintillation counting. Nonspecific binding was measured in the presence of 10 mM unlabeled GABA. Data analysis was performed using the non-linear regression algorithms in Prism. Data points represent average ± s.e.m. of triplicate measurements.

Disulfide design and western blot analysis {#S15}
------------------------------------------

The structure of (R)-baclofen~AGO~-GBR1b~VFT~:GBR2~VFT~ was used for the rational design of disulfide bonds at the LB2-LB2 heterodimer interface. The residue pair, GBR1b-T198 and GBR2-Q206 was identified by the software Disulfide by Design^[@R62]^ to have the proximity and geometry required for disulfide formation when mutated to cysteines. The T198C and Q206C mutations were engineered into full length GBR1b and GBR2 in pcDNA3.1(+), respectively.

HEK293 T/17 cells were transiently transfected with equal amounts of the full length GBR1b and GBR2 plasmids. Cells were harvested in a buffer containing 20 mM Tris, pH 7.5, 150 mM NaCl, and 1% dodecyl-maltoside. After the insoluble materials were removed by centrifugation, the supernatant was analyzed by 4--15% SDS polyacrylamide gel electrophoresis in the absence and presence of 100 mM DTT. In addition, formation of a disulfide-linked heterodimer between the cysteine mutant pair GBR1b-T198C and GBR2-Q206C was analyzed under two different conditions: in the absence of any ligand, and in the presence of 10 mM GABA. Heterodimer formation of all other samples was analyzed in the presence of 10 mM GABA. The samples were transferred to polyvinylidene fluoride (PVDF) membranes. After blocking with 5% milk, the membranes were incubated with a primary antibody. Mouse anti-Flag M1 antibody (Sigma) was used to detect the GBR1b protein. Mouse anti-HA antibody HA.11 clone 16B12 (Covance) was used to probe GBR2. Both were followed by an alkaline phosphatase (AP)-conjugated anti-mouse secondary antibody. Proteins were visualized by colorimetric method.

Supplementary Material {#SM}
======================

**Supplementary Information** is linked to the online version of the paper at [www.nature/com/nature](http://www.nature/com/nature).
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![Crystal structures of the GBR1b~VFT~:GBR2~VFT~ complex\
**a,** Apo structure. **b,** Antagonist CGP54626~ANT~-bound structure. **c,** Agonist (R)-baclofen~AGO~-bound structure. Each complex is shown in two views related by a 90°-rotation about the vertical axis. Front view (left panel) is shown as a ribbon diagram; side view (right panel) is presented as a molecular surface. GBR1b~VFT~ and GBR2~VFT~ are colored blue and green, respectively. The observed carbohydrates are shown as ball-and-stick models in gray. Disulfide bridges are in magenta. The ligands are displayed as space-filling models.](nihms528775f1){#F1}

![Agonist-induced conformational changes\
**a, b,** Superposition of apo (cyan) and (R)-baclofen~AGO~-bound (red) complexes based on the LB1 domain of GBR1b~VFT~ **(a)**, or GBR2~VFT~ **(b)**. Side view is shown on the right for the superimposed GBR1b~VFT~ **(a)** and GBR2~VFT~ **(b)** subunits. Green line is the axis of rotation that relates the LB2 domain of GBR1b~VFT~ (rotation χ = 29°, screw translation τ~χ~ = 0.2 Å) **(a)** or GBR2~VFT~ (rotation χ = 9°, screw translation τ~χ~ = 0.1 Å) **(b)** from the apo and agonist-bound structures.\
**c, d,** Surface representation of apo **(c)** and (R)-baclofen~AGO~-bound **(d)** GBR1b~VFT~:GBR2~VFT~ in front view (top), and bottom view (bottom). Distances between C-termini of the two subunits (yellow in apo structure; pink in (R)-baclofen~AGO~-bound structure) are marked by dashed lines.](nihms528775f2){#F2}

![Heterodimer interface\
**a,** Structure of apo-GBR1b~VFT~:GBR2~VFT~ with the elements involved in heterodimer formation highlighted by ribbons (LB1-LB1: B and C helices). **b,** Specific contacts at the LB1-LB1 heterodimer interface of apo-GBR1b~VFT~:GBR2~VFT~. The interface area is divided into three regions I, II, and III. Dashed lines indicate hydrogen bonds.\
**c,** Structure of (R)-baclofen~AGO~-GBR1b~VFT~:GBR2~VFT~ showing the elements involved in heterodimer formation (LB1-LB1: B and C helices; LB2-LB2: F and G helices, f and g strands, and connecting loops). **d,** Specific contacts at the LB2-LB2 heterodimer interface of (R)-baclofen~AGO~-GBR1b~VFT~:GBR2~VFT~. The interface area is divided into three regions IV, V, and VI. Dashed lines indicate hydrogen bonds.](nihms528775f3){#F3}

![Ligand recognition by GBR1b~VFT~\
**a, c,** Molecular surface of GBR1b~VFT~ bound to antagonist CGP54626~ANT~ **(a)** or agonist (R)-baclofen~AGO~ **(c)**. Ligand is displayed as a space-filling model.\
**b, d,** Specific contacts between GBR1b~VFT~ (gray) and CGP54626~ANT~ (yellow) **(b)** or (R)-baclofen~AGO~ **(d)**, viewed in the direction of the arrow in **a** or **c**. Mesh represents the final 2Fo-Fc electron density map contoured at 1σ. Hydrogen bonds are represented by black dashed lines.\
**e,** Comparison of the binding sites of agonist GABA and antagonist CGP54626~ANT~. **f,** Comparison of the binding sites of agonist (R)-baclofen~AGO~ and two related antagonists (S)-2-OH-saclofen~ANT~ and (R)-phaclofen~ANT~.\
**g, h,** Dose-dependent \[^3^H\]CGP54626~ANT~ binding **(g)** and GABA-stimulated \[^35^S\]GTPγS binding **(h)** in membranes from cells expressing wild type GABA~B~ receptor (GBR1b-wt + GBR2-wt) or the combination of GBR2-wt and various GBR1b mutants.](nihms528775f4){#F4}

![Constitutive activity of disulfide-tethered GBR1b:GBR2 heterodimer\
**a,** Position of cysteine mutations (spheres) at the LB2-LB2 heterodimer interface of (R)-baclofen~AGO~-GBR1b~VFT~:GBR2~VFT~.\
**b,** Western blot analysis of membranes from cells expressing different combinations of wild-type (WT) and mutant GABA~B~ receptor subunits (GBR1b-T198C, abbreviated as T198C; GBR2-Q206C, abbreviated as Q206C). The samples were assayed in the presence of 10 mM GABA under reducing (+DTT) and non-reducing (−DTT) conditions. The double cysteine mutant (T198C / Q206C) was also analyzed in the absence of ligand. GBR1b and GBR2 were detected by anti-Flag and anti-HA antibodies, respectively. Arrow 1, GBR1b-GBR2 heterodimer; arrow 2 and 4, GBR2 monomer; arrow 3 and 5, GBR1b monomer.\
**c,** GABA-stimulated dose-dependent \[^35^S\]GTPγS binding in membranes from cells expressing wild-type or various cysteine mutant receptors in the presence and absence of DTT.](nihms528775f5){#F5}
